By integrating findings from preclinical studies, randomized controlled trials, and meta-analyses, this review aims to provide a comprehensive understanding of the therapeutic potential of GLP-1 RAs in managing hypertension within the framework of diabetes and obesity care
Clinically proven medications: Get access to real GLP-1 drugs prescribed and monitored by licensed clinicians
Although the advised dose for treating depression ranged from 125 mg to 450 mg based on the previous study, the duration of therapeutic supplementation ranged from 7 to 20 months
GLP-1 RAs in the treatment of T2DM and weight loss effects GLP-1 RAs were licensed for the treatment of T2DM due to their ability to lower A1C and achieve the hemoglobin A1c (HbA1c) goal of 48 mmol/mol (6.5%), a history of type 1 or T2D, or evidence of a previous MI, stroke, hospitalization for unstable angina pectoris, or transient ischemic attack within 60 days of screening are excluded
The use of ferroptosis activator erastin or RSL3 can promote cancer cell death by inducing ferroptosis